ClinicalTrials.gg
CompletedNCT01919697Updated Jul 2, 2019Results posted

Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

A Phase 3 interventional study of Plecanatide in Chronic Idiopathic Constipation, sponsored by Bausch Health Americas, Inc.. Completed at 220 sites in 2 countries. Open to participants aged 18 Years to 81 Years. Per ClinicalTrials.gov, last updated 2019-07-02.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,370
Allocation
Non-randomized
Ages
18 Years to 81 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States — 48 open to participants now, 71 under way, 7 of them phase 3. Bronchiolitis Obliterans Syndrome · United States.

Enrollment
4th of 260
2,370 · median 45
Started
2013
with 13 others
Phase 3
30 of 300
4 open now
Registered
116th of 300
by date

Among the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States, this one is the 4th largest by enrollment of the 260 interventional ones that give a count, is one of 14 that started in 2013, is one of 30 in phase 3, and was the 116th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

48 of the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 81 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, open-label, 52-week safety and tolerability study of plecanatide in patients with Chronic Idiopathic Constipation (CIC).

Read the detailed description

This is an open-label extension study of plecanatide in the treatment of patients with CIC who previously completed Synergy Protocols SP304-20210 and SP304203-00 (The CIC3 Study).

The planned duration of each patient's study participation is up to 411 days, including up to 33 days of screening, 8 study visits over 52 weeks of treatment and a follow-up visit 2 weeks after the last dose of study drug.

03

Conditions studied

  • Chronic Idiopathic Constipation

Keywords

  • Plecantaide
  • Chronic Idiopathic Constipation
  • Chronic
  • Idiopathic
  • Constipation
  • Synergy
  • CIC
  • CIC study
  • CIC OLE
  • CIC OLE study
  • OLE
  • OLE CIC
  • OLE CIC3
  • Open label
  • Open label study
  • Long term
  • Long term study
  • Extension
  • Extension study
04

Who can participate

Ages eligible
18 Years to 81 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient completed a previous double-blind plecanatide study and was compliant with the study requirements.
  • Patient is in good health without unstable acute illness or exacerbation of an unstable chronic illness or chronic disease that may affect study assessments, particularly if there has been a significant change to health status since the previous plecanatide study.

Exclusion criteria

Exclusion Criteria:

  • Patient has had major surgery including laparoscopic procedures requiring general anesthesia within 60 days of Day 1.
  • Patient has a medical history of , or (HIV) infection.
  • Patient has taken a protocol-prohibited drug without the appropriate .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,370 participants (actual)

Study arms

  • Experimental
    Plecanatide 3.0 mg

    Plecanatide 3.0 mg, one tablet by mouth daily for 52 weeks

    Drug: Plecanatide

  • Experimental
    Plecanatide 6.0 mg

    Plecanatide 6.0 mg, one tablet by mouth daily for 52 weeks

    Drug: Plecanatide

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE)

    All clinically significant findings upon Physical Examinations of the Safety Population during the treatment period were reported as TEAEs. Safety was evaluated based on number of patients who experienced at least one TEAE.

    Time frame: From first dose up to 72 weeks

  2. Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) Leading to Discontinuation of Plecanatide

    Tolerability was evaluated based on number of patients who experienced at least one TEAE leading to discontinuation of the study drug

    Time frame: From first dose up to 72 weeks

  3. Summary of Vital Signs at >Day 364 - Blood Pressure (Systolic and Diastolic; mmHg)

    The vital signs included in the assessments were blood pressure (systolic and diastolic; mmHg), heart rate (beats per minute), body temperature (°C) and respiration rate (breaths per minute).

    Time frame: From first dose up to 72 weeks

  4. Summary of Vital Signs at >Day 364 - Heart Rate (Beats Per Minute)

    The vital signs included in the assessments were blood pressure (systolic and diastolic; mmHg), heart rate (beats per minute), body temperature (°C) and respiration rate (breaths per minute).

    Time frame: From first dose up to 72 weeks

  5. Summary of Vital Signs at >Day 364 - Body Temperature (°C)

    The vital signs included in the assessments were blood pressure (systolic and diastolic; mmHg), heart rate (beats per minute), body temperature (°C) and respiration rate (breaths per minute).

    Time frame: From first dose up to 72 weeks

  6. Summary of Vital Signs at >Day 364 - Respiration Rate (Breaths Per Minute)

    The vital signs included in the assessments were blood pressure (systolic and diastolic; mmHg), heart rate (beats per minute), body temperature (°C) and respiration rate (breaths per minute).

    Time frame: From first dose up to 72 weeks

  7. Summary of ECG Results Shift From Baseline at > Day 364

    Baseline was defined as the last non-missing value collected prior to first dose of study drug)

    Time frame: From first dose up to 72 weeks

  8. Summary of Treatment-Emergent Laboratory Abnormalities With At Least a 1-grade Shift From Baseline

    Baseline was defined as the last non-missing value collected prior to first dose of study drug within a given entry into the study. The Common Terminology Criteria for Adverse Events (CTCAE), Grades 1 through 5 were used for descriptions of severity for each Adverse Event (AE): Grade 1 - Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2 - Moderate; minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental Activities of Daily Living (ADL); Grade 3 - Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL; Grade 4 - Life-threatening consequences; urgent intervention indicated; Grade 5 - Death related to AE.

    Time frame: From first dose up to 72 weeks

Secondary outcomes

  1. Summary of Patient Patient Global Assessment (PGA) for Constipation Severity at > Day 364

    Constipation severity was measured using a 5-point score: 1=None, 2=Mild, 3=Moderate, 4=Severe, 5=Very severe Baseline was defined as the last non-missing value collected prior to first dose of study drug within a given entry into the study.

    Time frame: Form first dose up to 72 weeks

  2. Summary of Patient Global Assessment (PGA) for Constipation - Change From Baseline to > Day 364

    Change of Constipation measured using a 7-point score: 1=Very Much Improved, 2=Much Improved, 3=Minimally Improved, 4=No change, 5=Minimally Worse, 6=Much Worse, 7=Very Much Worse Baseline is defined as the last non-missing value collected prior to first dose of study drug within a given entry into the study.

    Time frame: From first dose up to 72 weeks

  3. Summary of Patient Global Assessment (PGA) for Treatment Satisfaction at > Day 364

    Baseline was defined as the last non-missing value collected prior to first dose of study drug within a given entry into the study. Treatment Satisfaction was measured using a 5-point score: 1=Not At All Satisfied, 2=A Little Satisfied, 3=Moderately Satisfied, 4=Quite Satisfied, 5=Very Satisfied.

    Time frame: From first dose up to 72 weeks

  4. Summary of Patient Global Assessment (PGA) for Treatment Continuation at End of Treatment

    Treatment continuation was measured using 5-point score: 1=Not At All Likely, 2=A Little Likely, 3=Moderately Likely, 4=Quite Likely, 5=Very Likely

    Time frame: From first dose up to 72 weeks

07

Results

Posted Jul 2, 2019

Participant flow

Patients with CIC who completed the double-blind phase 2b (NCT01429987) study, or phase 3 (NCT01982240 or NCT0222471) studies or who screen-failed for the phase 3 studies due solely to pre-treatment diary compliance and met all of the inclusion criteria and none of the exclusion criteria enrolled into this open-label study.

Participant flow — Overall Study
MilestonePlecanatide 3 mgPlecantide 6 mg
Started2242146
Completed1711761
Not completed53385

Outcome measures

PrimaryNumber of Patients With at Least One Treatment-Emergent Adverse Event (TEAE)

All clinically significant findings upon Physical Examinations of the Safety Population during the treatment period were reported as TEAEs. Safety was evaluated based on number of patients who experienced at least one TEAE.

Time frame:
From first dose up to 72 weeks
Reported as:
Count of participants · Participants
Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE)
ParticipantsPlecanatide 3 mgPlecantide 6 mg
Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE)123620
PrimaryNumber of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) Leading to Discontinuation of Plecanatide

Tolerability was evaluated based on number of patients who experienced at least one TEAE leading to discontinuation of the study drug

Time frame:
From first dose up to 72 weeks
Reported as:
Count of participants · Participants
Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) Leading to Discontinuation of Plecanatide
ParticipantsPlecanatide 3 mgPlecantide 6 mg
Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) Leading to Discontinuation of Plecanatide14111
PrimarySummary of Vital Signs at >Day 364 - Blood Pressure (Systolic and Diastolic; mmHg)

The vital signs included in the assessments were blood pressure (systolic and diastolic; mmHg), heart rate (beats per minute), body temperature (°C) and respiration rate (breaths per minute).

Time frame:
From first dose up to 72 weeks
Reported as:
Mean · mmHg
Summary of Vital Signs at >Day 364 - Blood Pressure (Systolic and Diastolic; mmHg)
mmHgPlecanatide 3 mgPlecantide 6 mg
Systolic Blood Pressure121 ± 13.40122.9 ± 14.11
Diastolic Blood Pressure75.7 ± 9.1976.5 ± 8.47
PrimarySummary of Vital Signs at >Day 364 - Heart Rate (Beats Per Minute)

The vital signs included in the assessments were blood pressure (systolic and diastolic; mmHg), heart rate (beats per minute), body temperature (°C) and respiration rate (breaths per minute).

Time frame:
From first dose up to 72 weeks
Reported as:
Mean · beats per minute
Summary of Vital Signs at >Day 364 - Heart Rate (Beats Per Minute)
beats per minutePlecanatide 3 mgPlecantide 6 mg
Summary of Vital Signs at >Day 364 - Heart Rate (Beats Per Minute)71.2 ± 10.0371.9 ± 9.30
PrimarySummary of Vital Signs at >Day 364 - Body Temperature (°C)

The vital signs included in the assessments were blood pressure (systolic and diastolic; mmHg), heart rate (beats per minute), body temperature (°C) and respiration rate (breaths per minute).

Time frame:
From first dose up to 72 weeks
Reported as:
Mean · °C
Summary of Vital Signs at >Day 364 - Body Temperature (°C)
°CPlecanatide 3 mgPlecantide 6 mg
Summary of Vital Signs at >Day 364 - Body Temperature (°C)36.62 ± 0.32936.59 ± 0.378
PrimarySummary of Vital Signs at >Day 364 - Respiration Rate (Breaths Per Minute)

The vital signs included in the assessments were blood pressure (systolic and diastolic; mmHg), heart rate (beats per minute), body temperature (°C) and respiration rate (breaths per minute).

Time frame:
From first dose up to 72 weeks
Reported as:
Mean · breaths per minute
Summary of Vital Signs at >Day 364 - Respiration Rate (Breaths Per Minute)
breaths per minutePlecanatide 3 mgPlecantide 6 mg
Summary of Vital Signs at >Day 364 - Respiration Rate (Breaths Per Minute)15.7 ± 2.0316.0 ± 2.31
PrimarySummary of ECG Results Shift From Baseline at > Day 364

Baseline was defined as the last non-missing value collected prior to first dose of study drug)

Time frame:
From first dose up to 72 weeks
Reported as:
Number · participants
Summary of ECG Results Shift From Baseline at > Day 364
participantsPlecanatide 3 mgPlecantide 6 mg
Change from Normal to Abnormal2742
Change from Adnormal to Normal1544
PrimarySummary of Treatment-Emergent Laboratory Abnormalities With At Least a 1-grade Shift From Baseline

Baseline was defined as the last non-missing value collected prior to first dose of study drug within a given entry into the study. The Common Terminology Criteria for Adverse Events (CTCAE), Grades 1 through 5 were used for descriptions of severity for each Adverse Event (AE): Grade 1 - Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2 - Moderate; minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental Activities of Daily Living (ADL); Grade 3 - Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL; Grade 4 - Life-threatening consequences; urgent intervention indicated; Grade 5 - Death related to AE.

Time frame:
From first dose up to 72 weeks
Reported as:
Number · participants
Summary of Treatment-Emergent Laboratory Abnormalities With At Least a 1-grade Shift From Baseline
participantsPlecanatide 3 mgPlecantide 6 mg
Summary of Treatment-Emergent Laboratory Abnormalities With At Least a 1-grade Shift From Baseline1921498
SecondarySummary of Patient Patient Global Assessment (PGA) for Constipation Severity at > Day 364

Constipation severity was measured using a 5-point score: 1=None, 2=Mild, 3=Moderate, 4=Severe, 5=Very severe Baseline was defined as the last non-missing value collected prior to first dose of study drug within a given entry into the study.

Time frame:
Form first dose up to 72 weeks
Reported as:
Mean · score on a scale
Summary of Patient Patient Global Assessment (PGA) for Constipation Severity at > Day 364
score on a scalePlecanatide 3 mgPlecantide 6 mg
Summary of Patient Patient Global Assessment (PGA) for Constipation Severity at > Day 3641.8 ± 0.941.7 ± 0.89
SecondarySummary of Patient Global Assessment (PGA) for Constipation - Change From Baseline to > Day 364

Change of Constipation measured using a 7-point score: 1=Very Much Improved, 2=Much Improved, 3=Minimally Improved, 4=No change, 5=Minimally Worse, 6=Much Worse, 7=Very Much Worse Baseline is defined as the last non-missing value collected prior to first dose of study drug within a given entry into the study.

Time frame:
From first dose up to 72 weeks
Reported as:
Mean · score on a scale
Summary of Patient Global Assessment (PGA) for Constipation - Change From Baseline to > Day 364
score on a scalePlecanatide 3 mgPlecantide 6 mg
Summary of Patient Global Assessment (PGA) for Constipation - Change From Baseline to > Day 3641.8 ± 0.941.7 ± 0.89
SecondarySummary of Patient Global Assessment (PGA) for Treatment Satisfaction at > Day 364

Baseline was defined as the last non-missing value collected prior to first dose of study drug within a given entry into the study. Treatment Satisfaction was measured using a 5-point score: 1=Not At All Satisfied, 2=A Little Satisfied, 3=Moderately Satisfied, 4=Quite Satisfied, 5=Very Satisfied.

Time frame:
From first dose up to 72 weeks
Reported as:
Mean · score on a scale
Summary of Patient Global Assessment (PGA) for Treatment Satisfaction at > Day 364
score on a scalePlecanatide 3 mgPlecantide 6 mg
Summary of Patient Global Assessment (PGA) for Treatment Satisfaction at > Day 3644.1 ± 1.134.2 ± 1.02
SecondarySummary of Patient Global Assessment (PGA) for Treatment Continuation at End of Treatment

Treatment continuation was measured using 5-point score: 1=Not At All Likely, 2=A Little Likely, 3=Moderately Likely, 4=Quite Likely, 5=Very Likely

Time frame:
From first dose up to 72 weeks
Reported as:
Mean · score on a scale
Summary of Patient Global Assessment (PGA) for Treatment Continuation at End of Treatment
score on a scalePlecanatide 3 mgPlecantide 6 mg
Summary of Patient Global Assessment (PGA) for Treatment Continuation at End of Treatment4.1 ± 1.224.1 ± 1.16

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Plecanatide 3 mg0/224 (0%)8/224 (3.6%)32/224 (14.3%)
Plecanatide 6 mg1/2,146 (0%)32/2,146 (1.5%)188/2,146 (8.8%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventPlecanatide 3 mgPlecanatide 6 mg
DiverticulitisInfections and infestations2/2240/2146
PregnancyPregnancy, puerperium and perinatal conditions1/2247/2146
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/2241/2146
Gastrooesophageal reflux diseaseGastrointestinal disorders1/2241/2146
Atrial fibrillationCardiac disorders1/2241/2146
Calculus uretericRenal and urinary disorders1/2240/2146
HydronephrosisRenal and urinary disorders1/2240/2146
Bile duct stoneHepatobiliary disorders1/2240/2146
HypotensionVascular disorders1/2240/2146
Psychotic disorderPsychiatric disorders1/2240/2146
Most frequent other events
Most frequent other events
EventPlecanatide 3 mgPlecanatide 6 mg
DiarrhoeaGastrointestinal disorders19/224150/2146
Urinary tract infectionInfections and infestations13/22438/2146

Baseline characteristics

A total of 2321 patients were based on the Safety Population (2370) excluding all duplicate patients except identified as "Index" patients. "Index" was duplicate patients appeared the first time in the enrollment.

Age, Continuous
Age, Continuous(years)Plecanatide 3 mgPlecanatide 6 mgTotal
Mean48.9 ± 11.7846.8 ± 14.0347.0 ± 13.84
Sex: Female, Male
Sex: Female, Male(Participants)Plecanatide 3 mgPlecanatide 6 mgTotal
Female19016871877
Male34410444
08

Study locations

220 sites
  • Synergy Research Site
    Birmingham, Alabama 35242, United States
  • Synergy Research Site
    Dothan, Alabama 36305, United States
  • Synergy Research Site
    Gulf Shores, Alabama 36542, United States
  • Synergy Research Site
    Huntsville, Alabama 35801, United States
  • Synergy Research Site
    Chandler, Arizona 85224, United States
  • Synergy Research Site
    Phoenix, Arizona 85018, United States
  • Synergy Research Site
    Tempe, Arizona 85283, United States
  • Synergy Research Site
    Tucson, Arizona 85704, United States
  • Synergy Research Site
    Tucson, Arizona 85712, United States
  • Synergy Research Site
    Tucson, Arizona 85716, United States
  • Synergy Research Site
    Little Rock, Arkansas 72211, United States
  • Synergy Research Site
    North Little Rock, Arkansas 72117, United States
  • Synergy Research Site
    Anaheim, California 92801, United States
  • Synergy Research Site
    Anaheim, California 92804, United States
  • Synergy Research Site
    Artesia, California 90701, United States
  • Synergy Research Site
    Carlsbad, California 92008, United States
  • Synergy Research Site
    Cerritos, California 90703, United States
  • Synergy Research Site
    Chula Vista, California 91910, United States
  • Synergy Research Site
    Corona, California 92879, United States
  • Synergy Research Site
    Encinitas, California 92024, United States
  • Synergy Research Site
    Fountain Valley, California 92708, United States
  • Synergy Research Site
    Fresno, California 93726, United States
  • Synergy Research Site
    Hawaiian Gardens, California 90716, United States
  • Synergy Research Site
    La Mirada, California 90638, United States
  • Synergy Research Site
    Laguna Hills, California 92653, United States
  • Synergy Research Site
    Lancaster, California 93534, United States
  • Synergy Research Site
    Long Beach, California 90806, United States
  • Synergy Research Site
    Los Angeles, California 90015, United States
  • Synergy Research Site
    Los Angeles, California 90045, United States
  • Synergy Research Site
    Mission Hills, California 91345, United States
  • Synergy Research Site
    North Hollywood, California 91606, United States
  • Synergy Research Site
    Orange, California 92868, United States
  • Synergy Research Site
    Pasadena, California 91105, United States
  • Synergy Research Site
    Sacramento, California 95821, United States
  • Synergy Research Site
    San Diego, California 92103, United States
  • Synergy Research Site
    San Diego, California 92108, United States
  • Synergy Research Site
    San Diego, California 92114, United States
  • Synergy Research Site
    Thousand Oaks, California 91360, United States
  • Synergy Research Site
    Colorado Springs, Colorado 80904, United States
  • Synergy Research Site
    Colorado Springs, Colorado 80907, United States
  • Synergy Research Site
    Colorado Springs, Colorado 80909, United States
  • Synergy Research Site
    Denver, Colorado 80218, United States
  • Synergy Research Site
    Denver, Colorado 80220, United States
  • Synergy Research Site
    Denver, Colorado 80246, United States
  • Synergy Research Site
    Littleton, Colorado 80128, United States
  • Synergy Research Site
    Bristol, Connecticut 06010, United States
  • Synergy Research Site
    Waterbury, Connecticut 06708, United States
  • Synergy Research Site
    Boynton Beach, Florida 33426, United States
  • Synergy Research Site
    Brandon, Florida 33511, United States
  • Synergy Research Site
    Clearwater, Florida 33756, United States
  • Synergy Research Site
    Clearwater, Florida 33759, United States
  • Synergy Research Site
    Cutler Bay, Florida 33189, United States
  • Synergy Research Site
    DeLand, Florida 32720, United States
  • Synergy Research Site
    Fort Lauderdale, Florida 33306, United States
  • Synergy Research Site
    Hialeah, Florida 33012, United States
  • Synergy Research Site
    Hialeah, Florida 33013, United States
  • Synergy Research Site
    Hialeah, Florida 33016, United States
  • Synergy Research Site
    Homestead, Florida 33030, United States
  • Synergy Research Site
    Jupiter, Florida 33458, United States
  • Synergy Research Site
    Lakeland, Florida 33805, United States
  • Synergy Research Site
    Miami Lakes, Florida 33016, United States
  • Synergy Research Site
    Miami Springs, Florida 33166, United States
  • Synergy Research Site
    Miami, Florida 33015, United States
  • Synergy Research Site
    Miami, Florida 33032, United States
  • Synergy Research Site
    Miami, Florida 33122, United States
  • Synergy Research Site
    Miami, Florida 33125, United States
  • Synergy Research Site
    Miami, Florida 33126, United States
  • Synergy Research Site
    Miami, Florida 33130, United States
  • Synergy Research Site
    Miami, Florida 33142, United States
  • Synergy Research Site
    Miami, Florida 33144, United States
  • Synergy Research Site
    Miami, Florida 33155, United States
  • Synergy Research Site
    Miami, Florida 33165, United States
  • Synergy Research Site
    Miami, Florida 33173, United States
  • Synergy Research Site
    Miami, Florida 33174, United States
  • Synergy Research Site
    Miami, Florida 33175, United States
  • Synergy Research Site
    Miami, Florida 33176, United States
  • Synergy Research Site
    Miami, Florida 33186, United States
  • Synergy Research Site
    Orlando, Florida 32801, United States
  • Synergy Research Site
    Orlando, Florida 32806, United States
  • Synergy Research Site
    Orlando, Florida 32807, United States
  • Synergy Research Site
    Pembroke Pines, Florida 33026, United States
  • Synergy Research Site
    Port Orange, Florida 32129, United States
  • Synergy Research Site
    Saint Petersburg, Florida 33709, United States
  • Synergy Research Site
    Tamarac, Florida 33319, United States
  • Synergy Research Site
    Tampa, Florida 33606, United States
  • Synergy Research Site
    Tampa, Florida 33607, United States
  • Synergy Research Site
    West Palm Beach, Florida 33409, United States
  • Synergy Research Site
    Athens, Georgia 30606, United States
  • Synergy Research Site
    Atlanta, Georgia 30342, United States
  • Synergy Research Site
    Decatur, Georgia 30032, United States
  • Synergy Research Site
    Decatur, Georgia 30033, United States
  • Synergy Research Site
    Oakwood, Georgia 30566, United States
  • Synergy Research Site
    Sandy Springs, Georgia 30328, United States
  • Synergy Research Site
    Savannah, Georgia 31406, United States
  • Synergy Research Site
    Smyrna, Georgia 30082, United States
  • Synergy Research Site
    Snellville, Georgia 30078, United States
  • Synergy Research Site
    Blackfoot, Idaho 83221, United States
  • Synergy Research Site
    Chicago, Illinois 60602, United States
  • Synergy Research Site
    Brownsburg, Indiana 46112, United States
  • Synergy Research Site
    Clive, Iowa 50325, United States

Showing the first 100 of 220 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Barish CF, Griffin P. Safety and tolerability of plecanatide in patients with chronic idiopathic constipation: long-term evidence from an open-label study. Curr Med Res Opin. 2018 Apr;34(4):751-755. doi: 10.1080/03007995.2018.1430024. Epub 2018 Feb 2. PubMed 29343131 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Jan 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2019, 3 years 6 months after primary completion. A results delay was requested in Aug 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2013
First posted
Aug 9, 2013
Start
Aug 2013
Primary completionActual
Jan 2016
CompletionActual
Mar 2016
Results delay requested
Aug 11, 2016
Results first posted
Jul 2, 2019
Last update
Jul 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01919697
Collaborators
Syneos Health
Responsible party
Sponsor
First posted
Aug 9, 2013
Start date
Aug 2013
Primary completion
Jan 2016
Completion
Mar 2016
Results posted
Jul 2, 2019
Last update
Jul 2, 2019

Study contacts

Richard A Krause, MD
principal investigator · ClinSearch, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Plecanatide

Start the discussion